Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a
wide array of anticancer drugs harboring distinct structures and mechanisms of action. The
multiple factors involved in mediating MDR may include host factors, tumor factors as well as
tumor-host interactions. Among the host factors are genetic variants and drug-drug
interactions. The plethora of tumor factors involves decreased drug uptake primarily via …